Main Logo
Logo

Society for Pediatric Radiology – Poster Archive

  261
  0
  0
 
 


Final ID: Paper #: 147

18F-FDG PET/CT Parameters are Correlated with MYCN Status in Newly Diagnosed Neuroblastoma

Purpose or Case Report: Despite significant advances in delivering dose-intensive and myeloablative therapy with hematopoietic stem cell support, the survival for patients presenting with metastatic neuroblastoma remains poor, with a 3 year event free survival (EFS) of about 60%. Modern treatment protocols are based on risk stratification which incorporates age of diagnosis, tumor stage, tumor histology, and molecular and cytogenetics including MYCN amplification. 18F-FDG PET/CT can play a role in disease staging and follow up. The purpose of this study was to report FDG PET findings in a cohort of children with neuroblastoma and assess for predictive associations with MYCN amplification status.
Methods & Materials: A single institution retrospective review was performed to identify all patients with newly diagnosed neuroblastoma for whom both pre-therapy 18F-FDG PET/CT and MYCN FISH were obtained between July 2006 and July 2019. All FDG-PET examinations had been performed utilizing 0.1-0.14 mCi/kg of FDG with imaging performed approximately 1 hour after radiopharmaceutical administration. Using the PET-edge tool in MIM (MIM Software; Cleveland, OH), a single observer drew regions of interest around the primary tumor to measure SUVmax, SUVmean, tumor volume, and total lesional glycolysis (TLG, SUVmean x tumor volume). All measurements were reviewed and adjusted as needed by a board certified Radiologist. Student’s t-test was used for comparisons of means.
Results: A total of 45 patients were identified. Thirteen (29%) patients had MYCN amplification. The mean age at diagnosis was 2.7 years ± 1.9 [standard deviation]. SUVmax ranged from 1.1 to 11.2 (mean 4.7 ± 2.3). Patients with MYCN amplification were older than those without MYCN amplification (3.6 ± 2.3 vs 2.4 ± 1.6 years, p = 0.04). Mean SUVmax (5.9 ± 2.4 vs 4.2 ± 2.1, p = 0.028), tumor volume (438 ± 335 mL vs 95 ± 96mL, p<0.0001), and TLG (1056 ± 845 vs 226 ± 329, p<0.0001) were significantly higher in MYCN amplified tumors versus non amplified tumors. SUVmax of the primary tumor was higher in patients with bone marrow metastases than those without (5.6 ± 2.0 vs 4.0 ± 2.3, p = 0.017).
Conclusions: On average, MYCN amplified neuroblastomas are larger and more metabolically active than MYCN non-amplified tumors. FDG PET may provide prognostic value in newly diagnosed neuroblastoma.
  • Sung, Andrew  ( Cincinnati Children's Hospital Medical Center, Department of Radiology , Cincinnati , Ohio , United States )
  • Weiss, Brian  ( Cincinnati Children's Hospital Medical Center, Department of Pediatrics, Division of Oncology , Cincinnati , Ohio , United States )
  • Trout, Andrew  ( Cincinnati Children's Hospital Medical Center, Department of Radiology , Cincinnati , Ohio , United States )
Session Info:

Scientific Session VI-A: Nuclear Medicine/Oncology

Nuclear Imaging/Oncology

SPR Scientific Papers

More abstracts on this topic:
Incidence of Abdominal Masses in Beckwidth-Wiedeman Hemihyperplasia and Non-Beckwidth Wiedemann Associated Hemihyperplasia

Raju Rajiv, Quijano Carla, Prada Carlos

Multisystem Imaging Findings of Pediatric Patients with PTEN Pathogenic Variants

De Leon-benedetti Laura, Martinez-rios Claudia, Tierradentro-garcia Luis, Kilicarslan Ozge, Caro Domínguez Pablo, Otero Hansel

More abstracts from these authors:
Due to circumstances surrounding the coronavirus pandemic, this final ePoster exhibit was not submitted.
You have to be authorized to contact abstract author. Please, Login or Signup.

Please note that this is a separate login, not connected with your credentials used for the SPR main website.

Not Available

Comments

We encourage you to join the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and stimulate conversation and knowledge sharing.

Please click here to review the full terms and conditions for engaging in the discussion, including refraining from product promotion and non-constructive feedback.

 

You have to be authorized to post a comment. Please, Login or Signup.

Please note that this is a separate login, not connected with your credentials used for the SPR main website.


   Rate this abstract  (Maximum characters: 500)